AN OPEN LABELLED EFFICACY AND TOLERABILITY STUDY OF NOVEL BETA-1- BLOCKER , NEBIVOLOL, ON HYPERTENSION WITH SPECIAL REFERENCE TO ENDOTHELIAL FUNCTION AND ARTERIAL STIFFNESS.

Trial Profile

AN OPEN LABELLED EFFICACY AND TOLERABILITY STUDY OF NOVEL BETA-1- BLOCKER , NEBIVOLOL, ON HYPERTENSION WITH SPECIAL REFERENCE TO ENDOTHELIAL FUNCTION AND ARTERIAL STIFFNESS.

Completed
Phase of Trial: Clinical Phase Unknown

Latest Information Update: 31 Aug 2016

At a glance

  • Drugs Nebivolol (Primary)
  • Indications Hypertension
  • Focus Therapeutic Use
  • Most Recent Events

    • 26 Mar 2012 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top